QPI-1002

from Wikipedia, the free encyclopedia

QPI-1002 is an experimental drug from the group of RNAi therapeutics for the treatment of acute kidney damage .

properties

QPI-1002 is an RNA that binds to the mRNA of p53 and leads to gene knockdown of p53 through RNA interference . It was in phase 3 clinical trials in 2017 .

Individual evidence

  1. ↑ KM Gallagher, S. O'neill, EM Harrison, JA Ross, SJ Wigmore, J. Hughes: Recent early clinical drug development for acute kidney injury. In: Expert opinion on investigational drugs. Volume 26, Number 2, February 2017, pp. 141-154, doi : 10.1080 / 13543784.2017.1274730 , PMID 27997816 .
  2. ↑ AM Ramos, C. González-Guerrero, A. Sanz, MD Sanchez-Niño, L. Rodríguez-Osorio, C. Martín-Cleary, B. Fernández-Fernández, M. Ruiz-Ortega, A. Ortiz: Designing drugs that combat kidney damage. In: Expert opinion on drug discovery. Volume 10, number 5, May 2015, pp. 541-556, doi : 10.1517 / 17460441.2015.1033394 , PMID 25840605 .
  3. ^ R. Titze-de-Almeida, C. David, SS Titze-de-Almeida: The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market. In: Pharmaceutical research. Volume 34, Number 7, July 2017, pp. 1339-1363, doi : 10.1007 / s11095-017-2134-2 , PMID 28389707 .